Skip Navigation


Cerebral Cortex Advance Access originally published online on October 26, 2006
Cerebral Cortex 2007 17(8):1948-1957; doi:10.1093/cercor/bhl104
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
17/8/1948    most recent
bhl104v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Férézou, I.
Right arrow Articles by Lambolez, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Férézou, I.
Right arrow Articles by Lambolez, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 The Authors
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Extensive Overlap of Mu-Opioid and Nicotinic Sensitivity in Cortical Interneurons

Isabelle Férézou1, Elisa L. Hill1, Bruno Cauli1, Nathalie Gibelin1, Takeshi Kaneko2, Jean Rossier1 and Bertrand Lambolez1

1 Laboratoire de Neurobiologie et Diversité Cellulaire, CNRS UMR 7637, École Supérieure de Physique et de Chimie Industrielles, 75005 Paris, France, 2 Department of Morphological Brain Science, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan

Address correspondence to Dr Bertrand Lambolez, NPA, CNRS UMR 7102, UPMC, 9 quai St Bernard, 75005 Paris, France. Email: bertrand.lambolez{at}snv.jussieu.fr.

We studied µ-opioid transmission in acute slices of rat neocortex using whole-cell recordings and single-cell reverse transcription–polymerase chain reaction. The µ-opioid receptor (MOR) was found in {gamma}-aminobutyric acidergic (GABAergic) interneurons that were either layer I cells frequently expressing neuropeptide Y or layers II–V cells expressing vasoactive intestinal peptide and enkephalin (Enk). We found that µ-opioid agonists inhibit these interneurons that are selectively excited by nicotinic agonists. The extensive overlap of µ-opioid and nicotinic responsiveness allowed µ-opioid agonists to inhibit nicotinic excitation of responsive interneurons and of their GABAergic output onto pyramidal cells. Finally, nicotinic stimulation resulted in a dynamic sequence where GABAergic transmission was first enhanced and then depressed below its baseline. This latter disinhibitory effect was prevented by a µ-opioid antagonist, indicating that excitation of nicotinic-responsive interneurons induced the release of endogenous Enk, which in turn led to MOR activation. Our results suggest that neocortical µ-opioid transmission acts as an inhibitory feedback onto nicotinic-responsive interneurons, which may change network excitability and inhibition patterns during cholinergic excitation.

Key Words: enkephalin • GABAergic interneuron • µ-opioid receptor • neocortex • nicotinic receptor

Funding to pay the Open Access publication charges for this article was provided by Grant-in-Aid for Scientific Research on Priority Areas (Molecular Brain Science) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (No. 17024055).


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.